| Description |
1 online resource |
| Series |
Immunology and immune system disorders |
|
Public health in the 21st century |
|
Immunology and immune system disorders.
|
|
Public health in the 21st century series.
|
| Contents |
AUTOANTIBODIES DETECTION, PATHOGENICITY AND HEALTH IMPLICATIONS ; AUTOANTIBODIES DETECTION, PATHOGENICITY AND HEALTH IMPLICATIONS ; CONTENTS ; PREFACE ; IMPLICATED AUTOANTIBODIES IN A KIDNEY DISEASE ; ABBREVIATIONS ; ADDITIONAL WELL KNOWN ABBREVIATIONS ; ABSTRACT ; INTRODUCTION ; AUTOIMMUNITY ; DETECTION OF AABS IN THE CIRCULATION AND IN SITU PATHOGENIC AAB RESPONSE AGAINST TARGET ANTIGENIC SITES IN THE KIDNEYS OF SPHN RATS ; PATHOGENICITY OF IGG AABS AGAINST KIDNEY AGS IN SPHN ; NON-PATHOGENIC IGM AABS AGAINST KIDNEY AGS IN SPHN ; HEALTH IMPLICATIONS |
|
PREVENTION AND TREATMENT OF A PATHOGENIC IGG AAB INITIATED AND MAINTAINED EXPERIMENTAL AUTOIMMUNE DISEASE BY THE MODIFIED VACCINATION TECHNIQUE (MVT) CONCLUSION ; ACKNOWLEDGMENTS ; REFERENCES ; ANTI-FACTOR H AUTOANTIBODIES IN KIDNEY DISEASE: DETECTION, PATHOGENIC ROLE AND RELEVANCE FOR TREATMENT; ABSTRACT ; INTRODUCTION ; FACTOR H; ANTI-FACTOR H AUTOANTIBODIES; Anti-Factor H Autoantibodies in Atypical Hemolytic Uremic Syndrome ; Anti-Factor H Autoantibodies in Dense Deposit Disease ; Anti-Factor H Autoantibodies in other Diseases ; DETECTION OF ANTI-FACTOR H AUTOANTIBODIES |
|
ARE ANTI-FACTOR H AUTOANTIBODIES PATHOGENIC? RELEVANCE OF THE AUTOANTIBODIES TO TREATMENT ; CONCLUSION ; ACKNOWLEDGMENTS ; REFERENCES ; AUTOANTIBODIES IN ALZHEIMER'S DISEASE ; ABSTRACT ; INTRODUCTION ; THE BLOOD-BRAIN-BARRIER (BBB): CONNECTION TO THE AD AUTOIMMUNITY HYPOTHESIS; AUTOANTIBODIES AGAINST AB PEPTIDES ; AUTOANTIBODIES AGAINST ATP SYNTHASE ; REDOX REACTIVE AUTOANTIBODIES ; AUTOANTIBODIES AGAINST NICOTINIC ACETYLOCHOLINE RECEPTORS ; AUTOANTIBODIES AGAINST GANGLIOSIDE GM1 ; AUTOANTIBODIES AGAINST OXIDIZED LOW-DENSITY LIPOPROTEIN |
|
AUTOANTIBODIES AGAINST SERINE/ARGININE PROTEIN KINASE 1 AUTOANTIBODY PROFILES IN HUMAN SERA ; CONCLUSION ; ACKNOWLEDGMENTS; REFERENCES; AUTOIMMUNITY IN CARDIOVASCULAR DISEASE; ABSTRACT ; COMMON ABBREVIATIONS USED IN THIS TEXT ; 1.0. DEFINITION OF AUTOIMMUNITY ; 2.0. CLINICAL SIGNIFICANCE OF DILATED CARDIOMYOPATHY AND PREECLAMPSIA ; 2.1. Dilated Cardiomyopathy Characteristics and Prevalence ; 2.2. Preeclampsia Characteristics and Prevalence ; 3.0. DILATED CARDIOMYOPATHY AUTOANTIBODY IMPORTANCE ; 3.1. Ý1-Adrenergic Receptor Agonistic Autoantibody (Ý1R-AA) |
|
3.2. Muscarinic M2 Receptor Agonistic Autoantibody (M2R-AA) 3.3. Clinical Significance ; 4.0. AUTOANTIBODY AND SIGNIFICANCE IN PREECLAMPSIA ; 4.1. In Vitro Studies of PE ; 4.2. Effects of PE in Various Laboratory and Clinical Settings ; A. Mouse Studies with Adoptive Transfer ; B. Rat Studies with Adoptive Transfer ; C. Human Evidence Supporting Autoantibody Role in PE ; 5.0. AUTOANTIBODY RECEPTOR BINDING AND PRODUCTION ; 5.1. Mechanisms Underlying Ý1R-AA Production ; 5.2. Mechanisms Underlying AT1-AA Production and Function; 6.0. THERAPEUTIC CONSIDERATIONS |
| Bibliography |
Includes bibliographical references and index |
| Notes |
English |
|
Print version record and CIP data provided by publisher |
| Subject |
Autoantibodies.
|
|
Autoantibodies -- Analysis.
|
|
Autoimmunity.
|
|
Autoantibodies
|
|
Autoimmunity
|
|
MEDICAL -- Immunology.
|
|
Autoantibodies
|
|
Autoantibodies -- Analysis
|
|
Autoimmunity
|
| Form |
Electronic book
|
| Author |
Jenkins, Graham E., editor
|
|
Hall, Joanne I., editor
|
| LC no. |
2020679769 |
| ISBN |
9781620815885 |
|
1620815885 |
|
